Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL4379980 | 0.82 | TP53 (0.58) | TP53GABRR1GRIK1GRIK2SLC7A5 | |
| Lactic Acid SCHEMBL28418627 | 0.82 | TP53 (0.58) | TP53GRIK1GRIK2SLC7A5 | |
| Allylamine SCHEMBL4940875 | 0.81 | — | — | |
| Lactic Acid SCHEMBL17631445 | 0.80 | TP53 (0.55) | TP53ALDH1A1GRIK1GRIK2SLC7A5 | |
| Valine SCHEMBL9126548 | 0.79 | SLC7A5 (0.65) | ALDH1A1GABRR1GRIK1GRIK2SLC7A5 | |
| Lactic Acid SCHEMBL16555873 | 0.78 | TP53 (0.69) | TP53ALDH1A1SLC7A5 | |
| Lactic Acid SCHEMBL31326881 | 0.78 | TP53 (0.69) | TP53GABRR1SLC7A5 | |
| Allylamine SCHEMBL28448040 | 0.78 | ALDH1A1 (0.56) | TP53ALDH1A1GABRR1GRIK1GRIK2 | |
| Lactic Acid SCHEMBL7195657 | 0.78 | — | — | |
| Allylamine SCHEMBL27553532 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015731-A1 | A TOPICAL ANTIVIRAL COMPOSITION CONTAINING A LOCAL ANESTHETIC AND METHOD OF MAKING THE SAME | NAL PHARMACEUTICALS, LTD. (CN) | 2016-01-21 | — | — | US | claimed |
| WO-2014159731-A1 | A TOPICAL ANTIVIRAL COMPOSITION CONTAINING A LOCAL ANESTHETIC AND METHOD OF MAKING THE SAME | NAL PHARMACEUTICALS, LTD (CN) | 2014-10-02 | — | — | WO | claimed |
| US-20140171490-A1 | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients | PHARMALINGT INC. (US) | 2014-06-19 | — | — | US | claimed |
| EP-1848541-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmalight Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006124899-A2 | PRODUCTION OF DERIVATIVES OF LACTIDE, PRODUCTION OF LACTIDES, AND USE OF LACTIDE IN FOODS AND TO PRODUCE POLYMERS | CARGILL, INCORPORATED (US) | 2006-11-23 | — | — | WO | claimed |
| WO-2006124633-A1 | PRODUCTION OF LACTIC ACID | CARGILL, INCORPORATED (US) | 2006-11-23 | — | — | WO | claimed |
| WO-2006082588-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | PHARMALIGHT INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20050069499-A1 | Foamable compositions, processes of preparing same and uses thereof | PERRIGO ISRAEL PHARMACEUTICALS LTD. (IL) | 2005-03-31 | — | — | US | claimed |
| US-12036310-B2 | Skin rejuvenating composition | Endoderm Laboratories, LLC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4308135-A1 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | Eligo Bioscience (FR) | 2024-01-24 | — | — | EP | disclosed |
| US-11839645-B2 | Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins | ELIGO BIOSCIENCE (FR) | 2023-12-12 | — | — | US | disclosed |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| WO-2023137098-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL SENSORY DISORDERS | WINSANTOR, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230218505-A1 | COSMETIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS | ELIGO BIOSCIENCE (FR) | 2023-07-13 | — | — | US | disclosed |
| US-5750732-A | SOLVENT EXTRACTION; DEHYDRATION | CHRONOPOL, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| CN-1136309-A | Method to produce cyclic esters | BIOPAK TECHNOLOGY LTD (US) | 1996-11-20 | — | — | CN | disclosed |
| EP-0722433-A4 | — | — | 1996-07-31 | — | — | EP | disclosed |
| EP-0722433-A1 | METHOD TO PRODUCE CYCLIC ESTERS | BioPak Technology, Ltd. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5420304-A | Esterification and cyclization then solvent extraction | BIOPAK TECHNOLOGY, LTD. (US) | 1995-05-30 | — | — | US | disclosed |
| WO-1995009142-A1 | METHOD TO PRODUCE CYCLIC ESTERS | BIOPAK TECHNOLOGY, LTD. (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | TP53 1224/4885ALDH1A1 90/4885GABRR1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.